MediciNova (MNOV) Competitors

$1.40 +0.03 (+2.19%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$1.40 +0.01 (+0.36%)

As of 05/14/2026 07:13 PM Eastern

MNOV vs. TRDA, CGEN, IKT, HELP, and NERV

Should you buy MediciNova stock or one of its competitors? MarketBeat compares MediciNova with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MediciNova include Entrada Therapeutics (TRDA), Compugen (CGEN), Inhibikase Therapeutics (IKT), Cybin (HELP), and Minerva Neurosciences (NERV). These companies are all part of the "pharmaceutical products" industry.

How does MediciNova compare to Entrada Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Entrada Therapeutics had 14 more articles in the media than MediciNova. MarketBeat recorded 17 mentions for Entrada Therapeutics and 3 mentions for MediciNova. MediciNova's average media sentiment score of 0.93 beat Entrada Therapeutics' score of 0.47 indicating that MediciNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entrada Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediciNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Entrada Therapeutics currently has a consensus price target of $18.25, indicating a potential upside of 167.20%. MediciNova has a consensus price target of $7.50, indicating a potential upside of 435.71%. Given MediciNova's stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Entrada Therapeutics has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by insiders. Comparatively, 14.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

MediciNova has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. MediciNova's return on equity of -26.32% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%
MediciNova	N/A	-26.32%	-24.55%

MediciNova has lower revenue, but higher earnings than Entrada Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$25.42M	10.43	-$143.75M	-$3.99	N/A
MediciNova	$410K	168.07	-$12M	-$0.24	N/A

Summary

MediciNova beats Entrada Therapeutics on 13 of the 17 factors compared between the two stocks.

How does MediciNova compare to Compugen?

Compugen (NASDAQ:CGEN) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Compugen and Compugen both had 3 articles in the media. MediciNova's average media sentiment score of 0.93 beat Compugen's score of 0.63 indicating that MediciNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediciNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compugen currently has a consensus price target of $5.00, indicating a potential upside of 65.02%. MediciNova has a consensus price target of $7.50, indicating a potential upside of 435.71%. Given MediciNova's stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Compugen has a beta of 2.79, suggesting that its share price is 179% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

12.2% of Compugen shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 14.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Compugen has a net margin of 48.57% compared to MediciNova's net margin of 0.00%. Compugen's return on equity of 55.68% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	48.57%	55.68%	29.68%
MediciNova	N/A	-26.32%	-24.55%

Compugen has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	3.94	$35.34M	$0.37	8.19
MediciNova	$410K	168.07	-$12M	-$0.24	N/A

Summary

Compugen beats MediciNova on 9 of the 16 factors compared between the two stocks.

How does MediciNova compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and MediciNova (NASDAQ:MNOV) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

MediciNova's return on equity of -26.32% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
MediciNova	N/A	-26.32%	-24.55%

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 7.3% of Inhibikase Therapeutics shares are owned by insiders. Comparatively, 14.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MediciNova has higher revenue and earnings than Inhibikase Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	N/A	N/A	-$48.26M	-$0.43	N/A
MediciNova	$410K	168.07	-$12M	-$0.24	N/A

Inhibikase Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

In the previous week, Inhibikase Therapeutics had 2 more articles in the media than MediciNova. MarketBeat recorded 5 mentions for Inhibikase Therapeutics and 3 mentions for MediciNova. MediciNova's average media sentiment score of 0.93 beat Inhibikase Therapeutics' score of 0.38 indicating that MediciNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
MediciNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibikase Therapeutics currently has a consensus price target of $5.50, indicating a potential upside of 195.70%. MediciNova has a consensus price target of $7.50, indicating a potential upside of 435.71%. Given MediciNova's higher possible upside, analysts clearly believe MediciNova is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	4 Strong Buy rating(s)	3.13
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Summary

MediciNova beats Inhibikase Therapeutics on 10 of the 15 factors compared between the two stocks.

How does MediciNova compare to Cybin?

Cybin (NASDAQ:HELP) and MediciNova (NASDAQ:MNOV) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

17.9% of Cybin shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 14.0% of MediciNova shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, MediciNova had 1 more articles in the media than Cybin. MarketBeat recorded 3 mentions for MediciNova and 2 mentions for Cybin. Cybin's average media sentiment score of 1.71 beat MediciNova's score of 0.93 indicating that Cybin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MediciNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MediciNova has higher revenue and earnings than Cybin. MediciNova is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A
MediciNova	$410K	168.07	-$12M	-$0.24	N/A

Cybin currently has a consensus price target of $58.75, indicating a potential upside of 1,061.07%. MediciNova has a consensus price target of $7.50, indicating a potential upside of 435.71%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than MediciNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Cybin has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

MediciNova's return on equity of -26.32% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-59.98%	-50.80%
MediciNova	N/A	-26.32%	-24.55%

Summary

Cybin beats MediciNova on 8 of the 15 factors compared between the two stocks.

How does MediciNova compare to Minerva Neurosciences?

MediciNova (NASDAQ:MNOV) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

9.9% of MediciNova shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 14.0% of MediciNova shares are held by company insiders. Comparatively, 10.4% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, MediciNova had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 3 mentions for MediciNova and 2 mentions for Minerva Neurosciences. MediciNova's average media sentiment score of 0.93 beat Minerva Neurosciences' score of 0.68 indicating that MediciNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediciNova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Minerva Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

MediciNova has higher revenue and earnings than Minerva Neurosciences. MediciNova is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	168.07	-$12M	-$0.24	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

MediciNova presently has a consensus price target of $7.50, indicating a potential upside of 435.71%. Minerva Neurosciences has a consensus price target of $10.50, indicating a potential upside of 90.91%. Given MediciNova's stronger consensus rating and higher probable upside, research analysts clearly believe MediciNova is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MediciNova has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market.

Minerva Neurosciences' return on equity of 0.00% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	N/A	-26.32%	-24.55%
Minerva Neurosciences	N/A	N/A	-32.63%

Summary

MediciNova beats Minerva Neurosciences on 12 of the 15 factors compared between the two stocks.

Get MediciNova News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNOV vs. The Competition

Export

Metric	MediciNova	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$67.43M	$3.42B	$6.34B	$12.38B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-5.83	18.47	20.89	25.63
Price / Sales	168.07	294.87	549.88	76.62
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	1.65	6.93	9.93	6.97
Net Income	-$12M	$24.11M	$3.55B	$333.62M
7 Day Performance	N/A	5.89%	1.70%	1.09%
1 Month Performance	-2.10%	-0.91%	0.49%	3.08%
1 Year Performance	0.72%	74.58%	39.41%	35.68%

MediciNova Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNOV MediciNova	3.0427 of 5 stars	$1.40 +2.2%	$7.50 +435.7%	+2.2%	$67.43M	$410K	N/A	10	Earnings Report Gap Up
TRDA Entrada Therapeutics	3.6658 of 5 stars	$7.12 +1.7%	$18.25 +156.3%	-14.3%	$271.74M	$25.42M	N/A	110	Earnings Report Analyst Revision High Trading Volume
CGEN Compugen	3.9086 of 5 stars	$2.83 -1.4%	$5.00 +76.7%	+131.3%	$271.37M	$72.76M	7.65	70	Upcoming Earnings Gap Down
IKT Inhibikase Therapeutics	2.0461 of 5 stars	$1.92 -5.4%	$5.50 +186.5%	N/A	$268.09M	$260K	N/A	6	News Coverage Positive News Earnings Report
HELP Cybin	3.8409 of 5 stars	$5.06 -0.8%	$58.75 +1,061.1%	N/A	$263.32M	N/A	N/A	50	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNOV) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MediciNova (MNOV) Competitors

MNOV vs. TRDA, CGEN, IKT, HELP, and NERV

How does MediciNova compare to Entrada Therapeutics?

Summary

How does MediciNova compare to Compugen?

Summary

How does MediciNova compare to Inhibikase Therapeutics?

Summary

How does MediciNova compare to Cybin?

Summary

How does MediciNova compare to Minerva Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV vs. The Competition

MediciNova Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MediciNova (MNOV) Competitors

MNOV vs. TRDA, CGEN, IKT, HELP, and NERV

How does MediciNova compare to Entrada Therapeutics?

Does the media prefer TRDA or MNOV?

Do analysts recommend TRDA or MNOV?

Which has more risk & volatility, TRDA or MNOV?

Do institutionals & insiders believe in TRDA or MNOV?

Is TRDA or MNOV more profitable?

Which has stronger earnings and valuation, TRDA or MNOV?

Summary

How does MediciNova compare to Compugen?

Does the media prefer CGEN or MNOV?

Do analysts recommend CGEN or MNOV?

Which has more risk & volatility, CGEN or MNOV?

Do institutionals & insiders believe in CGEN or MNOV?

Is CGEN or MNOV more profitable?

Which has stronger earnings and valuation, CGEN or MNOV?

Summary

How does MediciNova compare to Inhibikase Therapeutics?

Is IKT or MNOV more profitable?

Do institutionals & insiders believe in IKT or MNOV?

Which has higher earnings & valuation, IKT or MNOV?

Which has more risk and volatility, IKT or MNOV?

Does the media prefer IKT or MNOV?

Do analysts recommend IKT or MNOV?

Summary

How does MediciNova compare to Cybin?

Do institutionals & insiders believe in HELP or MNOV?

Does the media prefer HELP or MNOV?

Which has higher earnings & valuation, HELP or MNOV?

Do analysts recommend HELP or MNOV?

Which has more risk and volatility, HELP or MNOV?

Is HELP or MNOV more profitable?

Summary

How does MediciNova compare to Minerva Neurosciences?

Do institutionals and insiders believe in MNOV or NERV?

Does the media refer more to MNOV or NERV?

Which has better valuation & earnings, MNOV or NERV?

Do analysts rate MNOV or NERV?

Which has more volatility and risk, MNOV or NERV?

Is MNOV or NERV more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNOV vs. The Competition

MediciNova Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools